Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizonsFootnote

Peer review under responsibility of Arab Association of Urology.

References

• T.F.LueErectile dysfunctionN Engl J Med342200018021813
   PubMed Web of Science ®Google Scholar
• R.C.RosenJ.C.CappelleriM.D.SmithJ.LipskyB.M.PenaDevelopment and evaluation of an abridged, 5-item version of the international index of erectile function (IIEF-5) as a diagnostic tool for erectile dysfunctionInt J Impot Res111999319326
   PubMed Web of Science ®Google Scholar
• R.C.RosenA.RileyG.WagnerI.H.OsterlohJ.KirkpatrickA.MishraThe international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunctionUrology491997822830
   PubMed Web of Science ®Google Scholar
• E.J.MeulemanD.HatzichristouR.C.RosenR.SadovskyDiagnostic tests for male erectile dysfunction revisited. Committee consensus report of the international consultation in sexual medicineJ Sex Med7201023752381
   PubMed Web of Science ®Google Scholar
• R.W.LewisK.S.Fugl-MeyerR.BoschA.R.Fugl-MeyerE.O.LaumannE.Lizzaet alEpidemiology/risk factors of sexual dysfunctionJ Sex Med120043539
   PubMed Web of Science ®Google Scholar
• I.A.AytaJ.B.McKinlayR.J.KraneThe likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequencesBJU Int8419995056
   PubMed Web of Science ®Google Scholar
• C.B.JohannesA.B.AraujoH.A.FeldmanC.A.DerbyK.P.KleinmanJ.B.McKinlayIncidence of erectile dysfunction in men 40–69 years old: longitudinal results from the Massachusetts male aging studyJ Urol1632000460463
   PubMed Web of Science ®Google Scholar
• R.W.LewisD.HatzichristouE.LaumannEpidemiology and natural history of erectile dysfunction; risk factors including iatrogenic and agingA.JardinG.WagnerS.KhouryF.GiulianoProceedings of the first international consultation on erectile dysfunction2000Health PublicationPlymbridge (UK)2151
   Google Scholar
• A.SaloniaM.FerrariA.SaccàF.PellucchiG.CastagnaM.C.Clementiet alDelay in seeking medical help in patients with new-onset erectile dysfunction remained high over and despite the PDE5 era – an ecological studyJ Sex Med9201232393246
   PubMed Web of Science ®Google Scholar
• O.ShaeerK.ShaeerThe global online sexuality survey (GOSS): erectile dysfunction among arabic-speaking internet users in the middle eastJ Sex Med8201121522160
   PubMed Web of Science ®Google Scholar
• H.A.GhofraniI.H.OsterlohF.GrimmingerSildenafil. from angina to erectile dysfunction to pulmonary hypertension and beyondNat Rev Drug Discov52006689702
   PubMed Web of Science ®Google Scholar
• D.K.MontagueJ.H.BaradaA.M.BelkerL.A.LevineP.W.NadigC.G.Roehrbornet alClinical guidelines panel on erectile dysfunction: summary report on the treatment of organic erectile dysfunction. The American Urological AssociationJ Urol156199620072011
   PubMed Web of Science ®Google Scholar
• J.P.HeatonApomorphine. An update of clinical trial resultsInt J Impot Res12Suppl. 42000S67S73
   Google Scholar
• R.A.CostabileM.SpevakOral trazodone is not effective therapy for erectile dysfunction: a double-blind, placebo controlled trialJ Urol161199918191822
   PubMed Web of Science ®Google Scholar
• M.N.MoemenH.A.HamedI.I.KamelR.M.ShamloulH.M.GhanemClinical and sonographic assessment of the side effects of intracavernous injection of vasoactive substancesInt J Impot Res162004143145
   PubMed Web of Science ®Google Scholar
• S.G.KorenmanS.P.VioscaTreatment of vasculogenic sexual dysfunction with pentoxifyllineJ Am Geriatr Soc411993363366
   Web of Science ®Google Scholar
• J.B.KostisG.JacksonR.RosenE.Barrett-ConnorK.BillupsA.L.Burnettet alSexual dysfunction and cardiac risk (the second Princeton consensus conference)Am J Cardiol962005313321
   PubMed Web of Science ®Google Scholar
• G.B.BrockC.G.McMahonK.K.ChenT.CostiganW.ShenV.Watkinset alEfficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analysesJ Urol168200213321336
   PubMed Web of Science ®Google Scholar
• H.PorstH.Padma-NathanF.GiulianoG.AnglinL.VaraneseR.RosenEfficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trialUrology622003121125
   PubMed Web of Science ®Google Scholar
• J.D.CorbinS.H.FrancisPharmacology of phosphodiesterase-5 inhibitorsInt J Clin Pract562002453459
   PubMed Web of Science ®Google Scholar
• J.YuanR.ZhangZ.YangJ.LeeY.LiuJ.Tianet alComparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysisEur Urol632013902912
   PubMed Web of Science ®Google Scholar
• H.Padma-NathanW.D.SteersP.A.WickerEfficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. The Sildenafil study groupInt J Clin Pract521998375379
   PubMed Web of Science ®Google Scholar
• W.J.HellstromM.GittelmanG.KarlinT.SegersonM.ThibonnierT.Tayloret alVardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trialJ Androl232002763771
   PubMed Web of Science ®Google Scholar
• M.S.RendellJ.RajferP.A.WickerM.D.SmithSildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. The Sildenafil diabetes study groupJAMA2811999421426
   PubMed Web of Science ®Google Scholar
• I.GoldsteinJ.M.YoungJ.FischerK.BangerterT.SegersonT.TaylorVardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose studyDiabetes Care262003777783
   PubMed Web of Science ®Google Scholar
• I.Saenz de TejadaG.AnglinJ.R.KnightJ.T.EmmickEffects of tadalafil on erectile dysfunction in men with diabetesDiabetes Care25200221592164
   PubMed Web of Science ®Google Scholar
• E.K.HongH.LeporA.R.McCulloughTime dependent patient satisfaction with sildenafil for erectile dysfunction (ED) after nerve-sparing radical retropubic prostatectomy (RRP)Int J Impot Res11Suppl. 11999S15S22
   Google Scholar
• G.BrockA.NehraL.I.LipshultzG.S.KarlinM.GleaveM.Segeret alSafety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomyJ Urol170200312781283
   PubMed Web of Science ®Google Scholar
• F.MontorsiH.P.NathanA.McCulloughG.B.BrockG.BroderickS.Ahujaet alTadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trialJ Urol172200410361041
   PubMed Web of Science ®Google Scholar
• A.R.McCulloughAn update on the PDE-5 inhibitors (PDE-5i)J Androl24Suppl. 62003S528
   Google Scholar
• C.C.CarsonD.G.HatzichristouS.CarrierD.LordingP.LyngdorfP.Aliottaet alErectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trialBJU Int94200413011309
   PubMed Web of Science ®Google Scholar
• R.ShabsighJ.M.KaufmanC.SteidleH.Padma-NathanRandomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil aloneJ Urol1722004658663
   PubMed Web of Science ®Google Scholar
• G.CoronaM.MaggiThe role of testosterone in erectile dysfunctionNat Rev Urol720104656
   PubMed Web of Science ®Google Scholar
• H.Padma-NathanA.McCulloughC.ForestErectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy. Comparative phosphodiesterase-5 inhibitor efficacy for therapy and novel prevention strategiesCurr Urol Rep52004467471
   PubMedGoogle Scholar
• C.CarsonR.ShabsighS.SegalA.MurphyP.FredlundC.KuepferEfficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centersUrology652005353359
   PubMed Web of Science ®Google Scholar
• D.J.LeeP.CheethamK.K.BadaniPenile rehabilitation protocol after robot-assisted radical prostatectomy: assessment of compliance with phosphodiesterase type 5 inhibitor therapy and effect on early potencyBJU Int1052010382388
   Web of Science ®Google Scholar
• K.SairamE.KulinskayaG.B.BousteadD.C.HanburyT.A.McNicholasPrevalence of undiagnosed prostate cancer in men with erectile dysfunctionBJU Int892002261263
   PubMed Web of Science ®Google Scholar
• K.T.McVaryet alSildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trialJ Urol177200710711077
   PubMed Web of Science ®Google Scholar
• K.T.McVaryW.MonnigJ.L.CampsJr.J.M.YoungL.J.TsengG.van den EndeTadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasiaJ Urol177200714011407
   PubMed Web of Science ®Google Scholar
• S.L.ArcherE.D.MichelakisPhosphodiesterase type 5 inhibitors for pulmonary arterial hypertensionN Engl J Med361200918641871
   PubMed Web of Science ®Google Scholar
• A.A.AldashevB.K.KojonazarovT.A.AmatovT.M.SooronbaevM.M.MirrakhimovN.W.Morrellet alPhosphodiesterase type 5 and high altitude pulmonary hypertensionThorax602005683687
   PubMed Web of Science ®Google Scholar
• B.G.SchwartzL.A.LevineG.ComstockV.J.StecherR.A.KlonerCardiac uses of phosphodiesterase-5 inhibitorsJ Am Coll Cardiol592012915
   PubMed Web of Science ®Google Scholar
• T.J.CooperM.GuazziA.Al-MohammadO.AmirT.BengalJ.G.Clelandet alSildenafil in Heart failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial. Rationale and designEur J Heart Fail152013119122
   PubMed Web of Science ®Google Scholar
• I.GoldsteinA.R.McCulloughL.A.JonesW.J.HellstromC.H.BowdenK.Didonatoet alA randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunctionJ Sex Med9201211221133
   PubMed Web of Science ®Google Scholar
• B.H.KimH.S.LimJ.Y.ChungJ.R.KimK.S.LimD.R.Sohnet alSafety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjectsBr J Clin Pharmacol652008848854
   PubMed Web of Science ®Google Scholar
• J.S.KalsiP.D.KellS.CellekD.J.RalphNCX-911, a novel nitric oxide-releasing PDE5 inhibitor relaxes rabbit corpus cavernosum in the absence of endogenous nitric oxideInt J Impot Res162004195200
   PubMed Web of Science ®Google Scholar
• G.HackettP.KellD.RalphJ.DeanD.PriceM.Speakmanet alBritish society for sexual medicine guidelines on the management of erectile dysfunctionJ Sex Med5200818411865
   PubMed Web of Science ®Google Scholar